Menarini Group clinical trials

The registry lists 81 studies whose lead sponsor is Menarini Group or one of 10 companies grouped under it. 15 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 14, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 81. Browse all 81 →

• KATALYST-HEME-01: Study of the KAT6 Inhibitor MEN2312 in Heme MalignanciesNot yet recruitingNCT07873827Phase 1/2

  Sponsor listed in the registry: Stemline Therapeutics, Inc. · First submitted after Stemline Therapeutics, Inc. became part of Menarini Group

• A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast CancerRecruitingNCT07766018Phase 2

  Sponsor listed in the registry: Stemline Therapeutics, Inc. · First submitted after Stemline Therapeutics, Inc. became part of Menarini Group

• Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast CancerRecruitingNCT05386108Phase 1/2

  Sponsor listed in the registry: Stemline Therapeutics, Inc. · First submitted after Stemline Therapeutics, Inc. became part of Menarini Group

• A Study to Assess How Vaborem® is Taking up in the Body and Tolerated in Paediatric Patients With Gram Negative Infections, Including But Not Restricted to Complicated Urinary Tract InfectionsRecruitingNCT06828848Phase 2
• A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of RecurrenceRecruitingNCT06492616Phase 3

  Sponsor listed in the registry: Stemline Therapeutics, Inc. · First submitted after Stemline Therapeutics, Inc. became part of Menarini Group

• A Non-interventional Study of Participants With BPDCN Treated With ChemotherapyRecruitingNCT07785180

  Sponsor listed in the registry: Stemline Therapeutics, Inc. · First submitted after Stemline Therapeutics, Inc. became part of Menarini Group

• A Registry-study of ELZONRIS in Participants With BPDCNRecruitingNCT07785154

  Sponsor listed in the registry: Stemline Therapeutics, Inc. · First submitted after Stemline Therapeutics, Inc. became part of Menarini Group

• A First-in-Human Study of MEN2312 in Adults With Advanced Breast CancerRecruitingNCT06638307Phase 1

  Sponsor listed in the registry: Stemline Therapeutics, Inc. · First submitted after Stemline Therapeutics, Inc. became part of Menarini Group

• A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian CancerRecruitingNCT07226427Phase 1

  Sponsor listed in the registry: Stemline Therapeutics, Inc. · First submitted after Stemline Therapeutics, Inc. became part of Menarini Group

• Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat Dyslipidemia in Adults With Primary Non-familial Hypercholesterolemia or Mixed Dyslipidemia at High to Very High Cardiovascular Risk, During a Treatment Period of Approximately 84 DaysRecruitingNCT07614958Phase 3

  Sponsor listed in the registry: A. Menarini International Licensing S.A.

• Cell-based Non-invasive Prenatal Test WorkflowNot yet recruitingNCT07566780

  Sponsor listed in the registry: Menarini Silicon Biosystems · First submitted after Menarini Silicon Biosystems became part of Menarini Group

• A Study for CTC Expression and cfDNA/RNA Assessment in Metastatic Breast Cancer PatientsRecruitingNCT06833853

  Sponsor listed in the registry: Menarini Silicon Biosystems, INC · First submitted after Menarini Silicon Biosystems, INC became part of Menarini Group

• A Comparative Bioavailability Study of Two Torasemide 10 mg Tablets Formulations in Healthy Adult Participants Under Fasting Conditions:RecruitingNCT07201584Phase 1

  Sponsor listed in the registry: Berlin-Chemie AG Menarini Group · Berlin-Chemie AG Menarini Group — acquired company within the Menarini Group group

• A Comparative Bioavailability Study of Tamsulosin 0.4 mg Prolonged-release Tablets Versus the Reference Drug Omnic Ocas®, Tamsulosin Hydrochloride 0.4 mg, Prolonged-release Film-coated Tablets, in Healthy Adult Male Subjects, Under Fasting ConditionsRecruitingNCT07156916Phase 1

  Sponsor listed in the registry: Berlin-Chemie AG Menarini Group · Berlin-Chemie AG Menarini Group — acquired company within the Menarini Group group

• Prospective Observational Study On The Impact Of Nebilet In Blood Pressure Control In Hypertensive Patients (HYIMPACT)RecruitingNCT06938516

  Sponsor listed in the registry: A.Menarini Asia-Pacific Holdings Pte Ltd · First submitted after A.Menarini Asia-Pacific Holdings Pte Ltd became part of Menarini Group

• A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive ChemotherapyActive, not recruitingNCT06456463Phase 2

  Sponsor listed in the registry: Stemline Therapeutics, Inc. · First submitted after Stemline Therapeutics, Inc. became part of Menarini Group

• Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast CancerActive, not recruitingNCT05563220Phase 1/2

  Sponsor listed in the registry: Stemline Therapeutics, Inc. · First submitted after Stemline Therapeutics, Inc. became part of Menarini Group

• ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer StudyActive, not recruitingNCT05596409Phase 2

  Sponsor listed in the registry: Stemline Therapeutics, Inc. · First submitted after Stemline Therapeutics, Inc. became part of Menarini Group

• ACT-MBC: A Study of Circulating Tumor Cells (CTCs) in Metastatic Breast Cancer (MBC)Active, not recruitingNCT05662345

  Sponsor listed in the registry: Menarini Silicon Biosystems, INC · First submitted after Menarini Silicon Biosystems, INC became part of Menarini Group

• Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast CancerCompletedNCT03778931Phase 3

  Sponsor listed in the registry: Stemline Therapeutics, Inc. · First submitted before Stemline Therapeutics, Inc. became part of Menarini Group

• A Comparative Bioavalability Study of Tamsulosin 0.4 mg Prolonged-release Tablets Versus the Reference Drug Omnic Ocas®, Tabsulosine 0.4 mg Tablets in Healthy Adult Male Subjects, at Steady StateActive, not recruitingNCT07146711Phase 1

  Sponsor listed in the registry: Berlin-Chemie AG Menarini Group · Berlin-Chemie AG Menarini Group — acquired company within the Menarini Group group

• A Comparative Bioavailability Study of Tamsulosin 0.4 mg Prolonged-release Tablets Versus the Reference Drug Omnic Ocas®, Tamsulosin 0.4 mg Tablets, in Healthy Adult Male Subjects, Under Fed ConditionsActive, not recruitingNCT07091669Phase 1

  Sponsor listed in the registry: Berlin-Chemie AG Menarini Group · Berlin-Chemie AG Menarini Group — acquired company within the Menarini Group group

• MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast CancerCompletedNCT03767335Phase 1
• A Comparative Bioavailability Study of Reformulated Ibuprofen 2% and 4% Oral Suspensions (Berlin Chemie AG) and Versus Ibuprofen (Nurofen®) 200 mg/5 ml Oral SuspensionCompletedNCT07036861Phase 1

  Sponsor listed in the registry: Berlin-Chemie AG Menarini Group · Berlin-Chemie AG Menarini Group — acquired company within the Menarini Group group

• MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01)CompletedNCT04495621Phase 1/2
• MEN1703 (SEL24) in Participants With Acute Myeloid LeukemiaCompletedNCT03008187Phase 1/2
• Open-label inteRventional Clinical Trial to Assess Efficacy and Safety of the exteMporaneous combInation of Nebivolol and Ramipril in hypertenSIve pAtientsCompletedNCT06104423Phase 4

  Sponsor listed in the registry: Menarini International Operations Luxembourg SA

• A Trial of a Novel XPO1 Inhibitor in Participants With Advanced Solid TumorsCompletedNCT02667873Phase 1

  Sponsor listed in the registry: Stemline Therapeutics, Inc. · First submitted before Stemline Therapeutics, Inc. became part of Menarini Group

• Effectiveness and Safety of Combination of Nebivolol and Amlodipine in Hypertensive Patients Versus Each MonotherapyCompletedNCT05513937Phase 4

  Sponsor listed in the registry: Menarini International Operations Luxembourg SA

• Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma MultiformeCompletedNCT02078648Phase 1/2

  Sponsor listed in the registry: Stemline Therapeutics, Inc. · First submitted before Stemline Therapeutics, Inc. became part of Menarini Group

• Study Evaluating Dexketoprofen Trometamol/Tramadol Hydrochloride Analgesic Efficacy in Acute Low Back PainCompletedNCT05170841Phase 4

  Sponsor listed in the registry: Menarini International Operations Luxembourg SA

• Study of the PI3K Inhibitor SL-901 in Patients With Advanced Solid TumorsTerminatedNCT05382936Phase 1

  Sponsor listed in the registry: Stemline Therapeutics, Inc. · First submitted after Stemline Therapeutics, Inc. became part of Menarini Group

• Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF)CompletedNCT02268253Phase 1/2

  Sponsor listed in the registry: Stemline Therapeutics, Inc. · First submitted before Stemline Therapeutics, Inc. became part of Menarini Group

• A PK Study Testing Single Oral Dose of Elacestrant in Subjects With Normal or Severely Impaired Hepatic FunctionCompletedNCT06126575Phase 1

  Sponsor listed in the registry: Stemline Therapeutics, Inc. · First submitted after Stemline Therapeutics, Inc. became part of Menarini Group

• Effectiveness and Safety of Combination of Amlodipine and Zofenopril in Hypertensive Patients Versus Each MonotherapyCompletedNCT05279807Phase 4

  Sponsor listed in the registry: Menarini International Operations Luxembourg SA

• SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete RemissionTerminatedNCT02270463Phase 1/2

  Sponsor listed in the registry: Stemline Therapeutics, Inc. · First submitted before Stemline Therapeutics, Inc. became part of Menarini Group

• Effectiveness and Safety of Combination of Nebivolol and Zofenopril in Hypertensive patIents Versus Each MonotherapyCompletedNCT05257148Phase 4

  Sponsor listed in the registry: Menarini International Operations Luxembourg SA

• Study of MEN1112 Intravenous Infusion in Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT02353143Phase 1
• Levothyroxine-sodium Bioequivalence Trial With Oral Single Dose AdministrationCompletedNCT06547242Phase 1

  Sponsor listed in the registry: Berlin-Chemie AG Menarini Group · Berlin-Chemie AG Menarini Group — acquired company within the Menarini Group group

• Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid LeukemiaCompletedNCT02113982Phase 1/2

  Sponsor listed in the registry: Stemline Therapeutics, Inc. · First submitted before Stemline Therapeutics, Inc. became part of Menarini Group

• SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple MyelomaTerminatedNCT02661022Phase 1/2

  Sponsor listed in the registry: Stemline Therapeutics, Inc. · First submitted before Stemline Therapeutics, Inc. became part of Menarini Group

• Preliminary Efficacy, Safety and Pharmacokinetics Study of Nepadutant in Infant With Feeding IntoleranceCompletedNCT01532518Phase 2
• Fetal Cell Analysis From Maternal BloodStatus unknownNCT05671744Not applicable

  Sponsor listed in the registry: Menarini Biomarkers Singapore

• Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Breast CancerCompletedNCT03088527Phase 1

  Sponsor listed in the registry: Stemline Therapeutics, Inc. · First submitted before Stemline Therapeutics, Inc. became part of Menarini Group

• Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast CancerCompletedNCT02650817Phase 1

  Sponsor listed in the registry: Stemline Therapeutics, Inc. · First submitted before Stemline Therapeutics, Inc. became part of Menarini Group

• A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast CancerCompletedNCT02338349Phase 1

  Sponsor listed in the registry: Stemline Therapeutics, Inc. · First submitted before Stemline Therapeutics, Inc. became part of Menarini Group

• Observational Study of Efficacy, Safety and Tolerability of Fentanyl in Korean Cancer PatientsCompletedNCT03895762

  Sponsor listed in the registry: A.Menarini Asia-Pacific Holdings Pte Ltd · First submitted after A.Menarini Asia-Pacific Holdings Pte Ltd became part of Menarini Group

• Delafloxacin IV and OS Administration Compared to Best Available Therapy in Patients With Surgical Site InfectionsTerminatedNCT04042077Phase 3
• MEN1309 I.v. Infusion in Pts With CD205-positive Metastatic Solid Tumors and Relapsed or Refractory NHL Ph I StudyTerminatedNCT03403725Phase 1
• Olmesartan/HCTZ 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Essential HypertensionCompletedNCT00441350Phase 3